Combination therapy for resectable and unresectable adenocarcinoma of the pancreas

R. E. Falk, Frederick L Moffat, M. Lawler, J. Heine, L. Makowka

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The current report summarizes our experience with 77 patients with cancer of the pancreas treated over 3.5 years. Patients were not assigned to a definite group of therapy, but through the availability of different drugs and different types of treatment several comparable groups have evolved. All patients have received radiofrequency hyperthermia and chemotherapy, but in addition, some have received selective immune stimulation with one of two low-molecular-weight compounds. The data show that radiofrequency hyperthermia permits the use of a lower dose of chemotherapy, with an apparent response to treatment. This response is enhanced significantly by the addition of selective immune stimulation. A further, more rigorously defined study will be undertaken to confirm this data.

Original languageEnglish
Pages (from-to)685-688
Number of pages4
JournalCancer
Volume57
Issue number3
DOIs
StatePublished - Jun 3 1986
Externally publishedYes

Fingerprint

Pancreas
Adenocarcinoma
Fever
Drug Therapy
Group Psychotherapy
Pancreatic Neoplasms
Therapeutics
Molecular Weight
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination therapy for resectable and unresectable adenocarcinoma of the pancreas. / Falk, R. E.; Moffat, Frederick L; Lawler, M.; Heine, J.; Makowka, L.

In: Cancer, Vol. 57, No. 3, 03.06.1986, p. 685-688.

Research output: Contribution to journalArticle

Falk, R. E. ; Moffat, Frederick L ; Lawler, M. ; Heine, J. ; Makowka, L. / Combination therapy for resectable and unresectable adenocarcinoma of the pancreas. In: Cancer. 1986 ; Vol. 57, No. 3. pp. 685-688.
@article{c0d01ba1340f4fecb313f53049fd72e1,
title = "Combination therapy for resectable and unresectable adenocarcinoma of the pancreas",
abstract = "The current report summarizes our experience with 77 patients with cancer of the pancreas treated over 3.5 years. Patients were not assigned to a definite group of therapy, but through the availability of different drugs and different types of treatment several comparable groups have evolved. All patients have received radiofrequency hyperthermia and chemotherapy, but in addition, some have received selective immune stimulation with one of two low-molecular-weight compounds. The data show that radiofrequency hyperthermia permits the use of a lower dose of chemotherapy, with an apparent response to treatment. This response is enhanced significantly by the addition of selective immune stimulation. A further, more rigorously defined study will be undertaken to confirm this data.",
author = "Falk, {R. E.} and Moffat, {Frederick L} and M. Lawler and J. Heine and L. Makowka",
year = "1986",
month = "6",
day = "3",
doi = "10.1002/1097-0142(19860201)57:3<685::AID-CNCR2820570348>3.0.CO;2-X",
language = "English",
volume = "57",
pages = "685--688",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Combination therapy for resectable and unresectable adenocarcinoma of the pancreas

AU - Falk, R. E.

AU - Moffat, Frederick L

AU - Lawler, M.

AU - Heine, J.

AU - Makowka, L.

PY - 1986/6/3

Y1 - 1986/6/3

N2 - The current report summarizes our experience with 77 patients with cancer of the pancreas treated over 3.5 years. Patients were not assigned to a definite group of therapy, but through the availability of different drugs and different types of treatment several comparable groups have evolved. All patients have received radiofrequency hyperthermia and chemotherapy, but in addition, some have received selective immune stimulation with one of two low-molecular-weight compounds. The data show that radiofrequency hyperthermia permits the use of a lower dose of chemotherapy, with an apparent response to treatment. This response is enhanced significantly by the addition of selective immune stimulation. A further, more rigorously defined study will be undertaken to confirm this data.

AB - The current report summarizes our experience with 77 patients with cancer of the pancreas treated over 3.5 years. Patients were not assigned to a definite group of therapy, but through the availability of different drugs and different types of treatment several comparable groups have evolved. All patients have received radiofrequency hyperthermia and chemotherapy, but in addition, some have received selective immune stimulation with one of two low-molecular-weight compounds. The data show that radiofrequency hyperthermia permits the use of a lower dose of chemotherapy, with an apparent response to treatment. This response is enhanced significantly by the addition of selective immune stimulation. A further, more rigorously defined study will be undertaken to confirm this data.

UR - http://www.scopus.com/inward/record.url?scp=0022636445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022636445&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19860201)57:3<685::AID-CNCR2820570348>3.0.CO;2-X

DO - 10.1002/1097-0142(19860201)57:3<685::AID-CNCR2820570348>3.0.CO;2-X

M3 - Article

C2 - 3943007

AN - SCOPUS:0022636445

VL - 57

SP - 685

EP - 688

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -